Panic Attacks Are Linked To Poor Outcomes For Diabetic Patients, Group Health Study Finds
Main Category: DiabetesAlso Included In: Anxiety / Stress; Psychology / Psychiatry; Depression
Article Date: 26 Nov 2006 - 15:00 PDT
| Patient / Public: | ![]() |
4.43 (7 votes) |
| Healthcare Prof: | ![]() |
|
| Article Opinions: | 1 posts |
There is a strong link between panic episodes and increased complications from diabetes, according to a study conducted at Group Health Cooperative, a Seattle-based nonprofit health care system that coordinates care and coverage. The work appears in the November issue of General Hospital Psychiatry.
The researchers surveyed patients with diabetes about their symptoms, disability, social and emotional function, and quality of life. They also collected data on the patients' blood sugar levels, diabetic complications, and other illnesses.
The team had previously reported a strong link between diabetes and depression, which often goes along with panic disorders. They were interested in examining panic independently, however, to see whether patients who have panic without depression would also have poor diabetic outcomes.
"Panic attacks can mimic episodes of hypoglycemia (low blood sugar), so we need a better understanding of how the two conditions are related," explained Evette Ludman, PhD, lead author of the article and a research associate at Group Health. "We don't want people adjusting their blood sugar thinking they are having hypoglycemia when their symptoms are actually caused by a panic disorder."
Of the 4,385 patients surveyed, 193 reported experiencing recent episodes of panic or fear that caused them to change their immediate behavior. After accounting for the effect of depression, panic episodes were associated with higher blood sugar levels, increased diabetic complications and symptoms, greater disability, and lower self-rated health and functioning.
About half of the patients with panic also reported having major depression. By contrast, only 10 percent of patients without panic episodes had major depression.
Panic episodes may be a consequence of the diabetes itself, the researchers explain. Also, panic may interfere with patients' self-care and ability to follow their treatment plans.
If you have diabetes and you know that anxiety is an issue for you, you should talk to your doctor about possible treatment for your anxiety," advised Ludman. And doctors should carefully assess their patients with diabetes, looking for signs of depression or panic disorders, she added.
###
The study was funded by the National Institute of Mental Health.
About Group Health Center for Health Studies
Founded in 1947, Group Health is Seattle-based, consumer-governed, nonprofit health care system that coordinates care and coverage. The Group Health Center for Health Studies conducts research related to prevention, diagnosis, and treatment of major health problems. It is funded primarily through government and private research grants.
Contact: Joan DeClaire
Group Health Cooperative Center for Health Studies
Visit our diabetes section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/57216.php>
APA
http://www.medicalnewstoday.com/releases/57216.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Oramed: Solving A $132 Billion Problem!
posted by Sam Goodwin on 27 Nov 2006 at 7:15 amOramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of type 1 and 2 diabetes. Dr. Miriam Kidron, a pharmacologist and a biochemist on the Oramed team, states the path of insulin via the pill "imitates nature" since it passes to the liver and then to the bloodstream.
Pre-clinical studies have been successful, and the Oramed team is preparing for phase one clinical trials. Major drug companies have chosen not to compete with Oramed--it's easier to Buy out ORMP at much higher prices than it trades right now.
So now is the time to buy Oramed at the onset of Phase 1 trials and sell before the completion of Phase 2. For more info. on this very promising stock see:
http://www.marketwire.com/mw/release_html_b1?release_id=134997
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





